Fresh off the research radar — new HBOT science just published, summarized for our community.
Title:
Real-world data from the Mayo Clinic shows HBOT may ease symptoms in severe perianal Crohn’s disease — but long-term healing remains challenging
What this study looked at
Perianal Crohn’s disease is one of the most difficult forms of Crohn’s to treat.
When inflammation affects the anal region, painful fistulas and abscesses can develop. These can be extremely resistant to medication and often require repeated surgeries.
This study reviewed the medical records of six patients treated at the Mayo Clinic between 2014 and 2023 who received hyperbaric oxygen therapy as part of their management for refractory (treatment-resistant) perianal Crohn’s disease.
The goal was to see whether HBOT helped:
- reduce symptoms
- improve the appearance of fistulas on exam or imaging
- decrease the need for surgery
- change disease progression
HBOT protocol in this study
Patients received between 10 and 40 sessions of HBOT.
(The publication did not specify chamber pressure, but Mayo Clinic typically uses 2.0–2.4 ATA for inflammatory and wound-related conditions.)
Patients were also on standard Crohn’s treatments, including:
- immunosuppressive medications
- biologic therapies
- and in four cases, fecal diversion with either ileostomy or colostomy
Two patients had previously undergone total proctocolectomy with ileal-anal pouch creation.
Key findings
Symptomatic improvement in most patients
Four out of six patients reported less pain, less drainage and overall better comfort after HBOT.
Objective healing was limited
Only one patient showed measurable improvement on examination or imaging.
Disease progression continued for most
Apart from one individual, all patients eventually needed surgery within the following year, despite HBOT.
Important detail
These patients had very severe and long-standing disease, often after many failed therapies.
This represents the most difficult Crohn’s population — the ones who typically have no remaining medical options.
How to interpret this study
This is a small study, but it offers helpful real-world insights:
- HBOT appears to reduce symptoms, at least temporarily.
- It may help with local inflammation, drainage reduction and patient comfort.
- But for patients with advanced, structurally complicated disease, HBOT alone is not enough to prevent progression.
The authors emphasize that HBOT could serve as a supportive therapy but should not be expected to replace surgery or biologic therapy in severe cases.
Why this matters for the HBOT community
Many people ask whether HBOT can help inflammatory bowel disease — especially perianal disease, because oxygen is so central to tissue healing.
This study suggests:
- HBOT can provide symptomatic relief.
- It may help reduce local inflammation in the perianal tissues.
- Even in extremely severe cases, patients often feel better during treatment.
- But structural fistulas and deep tracts are difficult to reverse, regardless of therapy type.
Importantly, no negative effects were reported, reinforcing HBOT’s safety in this population.
Also relevant:
This patient group was receiving high-pressure hospital HBOT, but the anti-inflammatory mechanisms seen here have strong overlap with mild HBOT as well.
Takeaway for the community
Hyperbaric oxygen therapy may provide meaningful symptom relief for people with severe perianal Crohn’s disease — especially pain, drainage and local discomfort.
However, long-term healing of complex fistulas remains difficult, and most patients still require surgery.
HBOT can be considered as:
- a supportive therapy
- a comfort-enhancing therapy
- and a tool to reduce local inflammation
But not yet a stand-alone treatment for advanced perianal fistulas.
HBOT Radar will continue to highlight new studies on inflammatory bowel disease and healing of difficult wounds as they are published.
Study: https://pubmed.ncbi.nlm.nih.gov/41095923/
